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Nanoengineered Drug Combinations for Breast Cancer Treatment
To obtain dose-effect data, the hum an breast cancer cell line BT474 was incuba ted with the However, prior to determ ining the dose-effect cu rves for all drugs, it wa s necessary to optim ize drug incubation tim e. Incubation tim e had to be long enough to allow dr ug internalization as well as activation. For these studies, cells were incubated with DOC for 12, 24, 48, and 72 hours, and then analyzed with MTT assays. Th e results are seen in Fig. 1 . Reproducibility seemed to increase with incubation time, and the theoretical dose-effect model best fit data from 72 hour incubations. T he poor consistency observed at short incubation times was likely due to the lag time between drug internalization and drug action. In addition, the D 50 value measured after 72 hour drug incubation was 23.2 µM which matched with previously reported values (33.1 +/-9.3 µM) [2] . Therefore, a 72 hour incubation period was chosen for all dose-effect studies. It became apparent, however, that exact concentrations of drugs cannot be con trolled with the proposed dual drug carrier since th e number of pa rticles which accum ulates at target sites can vary widely. Rather, it is drug ratios that can be controlled. Therefore it was necessary to find a drug pair which is consistently synergistic at some optimal ratio. Since 5-FU and DOX see med to be the m ost promising drug pair in this scope, various ratios were investigated with this pair until a consistently synergistic ratio was identified. These studies yielded an optimal 5-FU:DOX ratio of 819:1 µM, demonstrated in Fig. 4a . F or various concentrations at this ratio, 5-FU and DOX exhibited synergism (CI <1). This contrast s with equal potency combinations of 5-FU and of the drug concentrations inve stigated. Thus, this drug pair will be used for biphasic particle encapsulation in future work.
IV. Reportable Outcomes
Kathryn Camacho, UCSB graduate student in chemical engineering, has advanced to PhD candidacy based off of her work in this project.
V. Conclusion
Dual drug-loaded nanoparticles can allow for co -localization of drugs at target sites and maintenance of synergistic ratios, leading to more effective and efficient combination therapies.
This project aim s to develop dual drug-load ed nanoparticles for the co-adm inistration of synergistic chemotherapy drugs. In particular, biphasic particles which were developed at the University of Michigan are su itable particles for multiple drug loading. Studies this past y ear identified synergism between FDA-approved breast cancer drugs. A highly synergistic drug pair of 5-FU:DOX at 819:1 µM was identif ied, and will be loa ded into bip hasic particles for coadministration in the ongoing studies.
VI.
